| abstract |
The present invention relates to methods uses and compositions for the treatment of an autoimmune disorder associated with myelin injury in the central nervous system (CNS), and particularly, multiple sclerosis (MS). More particularly, the invention relates to the use of an octapeptide derived from the connecting peptide of urokinase plasminogen activator (uPA), comprising the amino acid sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu also denoted by SEQ ID NO: 1, and any variant or derivative thereof, in the treatment of MS. The invention further provides for methods and compositions employing the octapeptide. |